These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 25940912)
21. IFN-α kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study. Houssiau FA; Thanou A; Mazur M; Ramiterre E; Gomez Mora DA; Misterska-Skora M; Perich-Campos RA; Smakotina SA; Cerpa Cruz S; Louzir B; Croughs T; Tee ML Ann Rheum Dis; 2020 Mar; 79(3):347-355. PubMed ID: 31871140 [TBL] [Abstract][Full Text] [Related]
22. A promising approach to targeting type 1 IFN in systemic lupus erythematosus. Chaichian Y; Wallace DJ; Weisman MH J Clin Invest; 2019 Mar; 129(3):958-961. PubMed ID: 30776023 [TBL] [Abstract][Full Text] [Related]
23. Type I interferon as a target of treatment in SLE. Lee PY; Reeves WH Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):323-30. PubMed ID: 17214578 [TBL] [Abstract][Full Text] [Related]
24. Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study. Ducreux J; Houssiau FA; Vandepapelière P; Jorgensen C; Lazaro E; Spertini F; Colaone F; Roucairol C; Laborie M; Croughs T; Grouard-Vogel G; Lauwerys BR Rheumatology (Oxford); 2016 Oct; 55(10):1901-5. PubMed ID: 27354683 [TBL] [Abstract][Full Text] [Related]
25. The important roles of type I interferon and interferon-inducible genes in systemic lupus erythematosus. Luo S; Wang Y; Zhao M; Lu Q Int Immunopharmacol; 2016 Nov; 40():542-549. PubMed ID: 27769023 [TBL] [Abstract][Full Text] [Related]
26. An evaluation of anifrolumab for use in adults with systemic lupus erythematosus. Ahmed AA; Osman N; Furie R Expert Rev Clin Immunol; 2022 Nov; 18(11):1095-1106. PubMed ID: 36083692 [TBL] [Abstract][Full Text] [Related]
27. FCgammaRII (CD32)-dependent induction of interferon-alpha by serum from patients with lupus erythematosus. Batteux F; Palmer P; Daëron M; Weill B; Lebon P Eur Cytokine Netw; 1999 Dec; 10(4):509-14. PubMed ID: 10586117 [TBL] [Abstract][Full Text] [Related]
28. Expression of the markers BDCA-2 and BDCA-4 and production of interferon-alpha by plasmacytoid dendritic cells in systemic lupus erythematosus. Blomberg S; Eloranta ML; Magnusson M; Alm GV; Rönnblom L Arthritis Rheum; 2003 Sep; 48(9):2524-32. PubMed ID: 13130472 [TBL] [Abstract][Full Text] [Related]
29. Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-α receptor antibody. Wang B; Higgs BW; Chang L; Vainshtein I; Liu Z; Streicher K; Liang M; White WI; Yoo S; Richman L; Jallal B; Roskos L; Yao Y Clin Pharmacol Ther; 2013 Jun; 93(6):483-92. PubMed ID: 23511714 [TBL] [Abstract][Full Text] [Related]
30. Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus. Gensous N; Lazaro E; Blanco P; Richez C Expert Rev Clin Immunol; 2024; 20(1):21-30. PubMed ID: 37800604 [TBL] [Abstract][Full Text] [Related]
31. Elevated levels of endogenous apoptotic DNA and IFN-alpha in complement C4-deficient mice: implications for induction of systemic lupus erythematosus. Finke D; Randers K; Hoerster R; Hennig H; Zawatzky R; Marion T; Brockmann C; Klempt-Giessing K; Jacobsen K; Kirchner H; Goerg S Eur J Immunol; 2007 Jun; 37(6):1702-9. PubMed ID: 17506029 [TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-γ IgG1 monoclonal antibody, in patients with systemic lupus erythematosus. Chen P; Vu T; Narayanan A; Sohn W; Wang J; Boedigheimer M; Welcher AA; Sullivan B; Martin DA; Ruixo JJ; Ma P Pharm Res; 2015 Feb; 32(2):640-53. PubMed ID: 25213774 [TBL] [Abstract][Full Text] [Related]
33. Treatment of systemic lupus erythematosus: new advances in targeted therapy. Lo MS; Tsokos GC Ann N Y Acad Sci; 2012 Jan; 1247():138-52. PubMed ID: 22236448 [TBL] [Abstract][Full Text] [Related]
34. Systemic Lupus Erythematosus--A Disease with A Dysregulated Type I Interferon System. Hagberg N; Rönnblom L Scand J Immunol; 2015 Sep; 82(3):199-207. PubMed ID: 26099519 [TBL] [Abstract][Full Text] [Related]
35. Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab. Tang W; Tummala R; Almquist J; Hwang M; White WI; Boulton DW; MacDonald A Clin Pharmacokinet; 2023 May; 62(5):655-671. PubMed ID: 37148484 [TBL] [Abstract][Full Text] [Related]
36. The importance of the type I interferon system in autoimmunity. Rönnblom L Clin Exp Rheumatol; 2016; 34(4 Suppl 98):21-4. PubMed ID: 27586799 [TBL] [Abstract][Full Text] [Related]
37. New therapeutic targets in systemic lupus. Sifuentes Giraldo WA; García Villanueva MJ; Boteanu AL; Lois Iglesias A; Zea Mendoza AC Reumatol Clin; 2012; 8(4):201-7. PubMed ID: 22483661 [TBL] [Abstract][Full Text] [Related]